Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Lanreotide - Ipsen

Next Previous
Drug Profile

Lanreotide - Ipsen

Alternative Names: Angiopeptin; BIM 23014; BIM 23014C; BM 23014; Dermopeptin; Ipstyl; ITM-014; ITM-014T; Lanreotide acetate; Lanreotide Autogel; Lanreotide PRF; Somatulina; Somatuline; Somatuline Autogel; Somatuline Depot; Somatuline LA; Somatuline LP

Latest Information Update: 05 Nov 2023

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Northwell Health; Tulane University
  • Developer Ipsen; Ipsen Biopharmaceuticals; Northwell Health; Radboud University Nijmegen Medical Centre; Teijin Pharma
  • Class Antineoplastics; Cyclic peptides; Eye disorder therapies; Pancreatic hormones; Pituitary hormone release inhibiting hormones; Urologics; Vascular disorder therapies
  • Mechanism of Action Growth hormone-releasing hormone inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Acromegaly; Pituitary cancer
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Acromegaly; Gigantism; Graves ophthalmopathy; Malignant carcinoid syndrome; Neuroendocrine tumours; Pituitary cancer
  • Phase II Gastrointestinal motility disorders; Pancreatic cancer
  • Discontinued Atherosclerosis; Breast cancer; Carcinoma; Coronary artery restenosis; Diabetic retinopathy; Digestive system disorders; Gastrointestinal cancer; Intestinal obstruction; Leiomyoma; Lung cancer; Polycystic kidney disease; Polycystic liver disease; Portal hypertension; Prostate cancer; Rheumatic disorders

Most Recent Events

  • 13 Jan 2023 Ipsen completes a phase III trial in Neuroendocrine tumours (Inoperable/Unresectable, Late-stage, Metastatic disease) in China (NCT04852679)
  • 07 Jun 2022 Merck completed a phase I/II PLANET trial in Neuroendocrine tumours (Second-line therapy or greater, Metastatic disease, Late-stage disease, Combination therapy) in USA (IV), in June 2022 (NCT03043664)
  • 13 Oct 2021 Columbia university in collaboration with Ipsen initiates enrolment in the phase II LAMPARA trial trial for neuroendocrine tumours (Late-stage disease, Second-line therapy or greater) in USA (SC, Injection) in June 2019 (NCT03946527)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top